非アルコール性脂肪性肝炎（NASH）の世界市場レポート 2025年

非アルコール性脂肪性肝炎（NASH）市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR32.8%で190億7,000万米ドルに成長します。予測期間の成長は、NASH治療薬開発の進展、NASHスクリーニングイニシアチブの増加、医療費の上昇、共同研究努力、政府支援、規制などに起因すると考えられます。予測期間における主な動向には、生活習慣への介入と患者教育への注力、臨床研究における共同研究の増加、規制の進展とパスウェイの指定、診断とモニタリングにおける人工知能の統合などがあります。

肥満の有病率の増加が非アルコール性脂肪性肝炎（NASH）市場の需要を牽引しています。肥満は、重大な健康リスクをもたらす脂肪の異常または過剰な蓄積、および特定の身長の人にとって健康的と考えられる体重を超えることを特徴とします。肥満の流行に関連した非アルコール性脂肪性肝疾患の罹患率の増加に伴い、NASHは今後数十年で重篤な肝疾患の主要な原因のひとつになると予測され、NASH治療薬や関連薬の需要が高まっています。例えば、2024年3月、英国を拠点とする国際公衆衛生機関である世界保健機関（WHO）は、2022年には18歳以上の成人が約25億人太りすぎに分類され、そのうち8億9000万人が肥満とともに生活していると報告しました。このように、肥満症例の増加は非アルコール性脂肪性肝炎（NASH）市場の成長を促進すると予想されます。

老人人口の増加は、非アルコール性脂肪性肝炎（NASH）市場の需要を促進する主な要因です。老年人口は65歳以上の高齢者を指し、加齢に伴う特有のヘルスケアニーズを示します。NASH市場における治療法の継続的な開拓と進歩は、高齢者の全体的な健康状態を改善し、高齢者に蔓延する肝臓関連疾患に対処する上で重要な役割を果たしています。2022年10月に世界保健機関（WHO）が指摘したように、世界の高齢者人口は大幅に増加し、2030年には6人に1人が60歳以上、2050年には21億人の高齢者が誕生すると予測されています。この人口動態の変化は、非アルコール性脂肪性肝炎（NASH）市場の成長を促進する上で、老人人口の増加が不可欠な役割を果たすことを強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界非アルコール性脂肪性肝炎（NASH） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の非アルコール性脂肪性肝炎（NASH）市場：成長率分析
• 世界の非アルコール性脂肪性肝炎（NASH）市場の実績：規模と成長, 2019-2024
• 世界の非アルコール性脂肪性肝炎（NASH）市場の予測：規模と成長, 2024-2029, 2034F
• 世界非アルコール性脂肪性肝炎（NASH）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非アルコール性脂肪性肝炎（NASH）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 固体
• 液体
• 世界の非アルコール性脂肪性肝炎（NASH）市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビタミンEとピオグリタゾン
• オカリバ
• エラフィブラノール
• セロンセルチブとセニクリビロック
• その他の製品
• 世界の非アルコール性脂肪性肝炎（NASH）市場病気の原因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高血圧
• 心臓病
• 高血中脂質
• 2型糖尿病
• 肥満
• 世界の非アルコール性脂肪性肝炎（NASH）市場：販売チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンラインプロバイダー
• 世界の非アルコール性脂肪性肝炎（NASH）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の非アルコール性脂肪性肝炎（NASH）市場、固体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• カプセル
• その他の固形剤形
• 世界の非アルコール性脂肪性肝炎（NASH）市場、液体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口溶液
• シロップ
• 注射液
• その他の液体剤形

第7章 地域別・国別分析

• 世界の非アルコール性脂肪性肝炎（NASH）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の非アルコール性脂肪性肝炎（NASH）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非アルコール性脂肪性肝炎（NASH）市場：競合情勢
• 非アルコール性脂肪性肝炎（NASH）市場：企業プロファイル
  • NGM Biopharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• The Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Genfit SA
• Cadila Pharmaceuticals Ltd.
• Intercept Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
• Blade Therapeutics Inc.
• Galmed Pharmaceuticals Inc.
• Immuron Limited
• Terns Pharmaceuticals Inc.
• Tobira Therapeutics Inc.
• Arena Pharmaceuticals Inc.
• Galectin Therapeutics Inc.
• Viking Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非アルコール性脂肪性肝炎（NASH）市場2029：新たな機会を提供する国
• 非アルコール性脂肪性肝炎（NASH）市場2029：新たな機会を提供するセグメント
• 非アルコール性脂肪性肝炎（NASH）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-alcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease, distinguished by inflammation of the liver, and has the potential to progress to cirrhosis and liver failure.

Non-alcoholic steatohepatitis (NASH) is classified into solid and liquid forms. Solid variants are predominantly produced in crystalline forms, sold in tablet formats for oral consumption, owing to their superior purity and durability. Products in this category, such as vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others, target various health conditions including hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. These products are distributed through hospital pharmacies, retail pharmacies, and online providers, encompassing both oral and parenteral applications.

The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $4.5 billion in 2024 to $6.13 billion in 2025 at a compound annual growth rate (CAGR) of 36.1%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development.

The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 32.8%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.

The increasing prevalence of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity is characterized by an abnormal or excessive accumulation of fat that poses significant health risks, as well as a body weight exceeding what is considered healthy for a person of a specific height. With the growing incidence of non-alcoholic fatty liver disease linked to the obesity epidemic, NASH is projected to become one of the leading causes of severe liver disease in the coming decades, heightening the demand for NASH treatments and related medications. For example, in March 2024, the World Health Organization (WHO), a UK-based international public health organization, reported that in 2022, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Thus, the rise in obesity cases is expected to drive the growth of the non-alcoholic steatohepatitis (NASH) market.

The rising demographic of the geriatric population is a key driver fueling the demand for the non-alcoholic steatohepatitis (NASH) market. The geriatric population, representing individuals aged 65 and older, exhibits specific healthcare needs associated with aging. The ongoing development and advancements in treatments within the NASH market play a crucial role in enhancing overall health outcomes for the elderly, addressing a prevalent liver-related condition prevalent in aging individuals. As indicated by the World Health Organization in October 2022, the global elderly population is anticipated to witness a significant increase, with 1 in 6 individuals being 60 or older by 2030 and an estimated 2.1 billion elderly people by 2050. This demographic shift underscores the imperative role of the increasing geriatric population in driving the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Major companies in the non-alcoholic steatohepatitis (NASH) market are focusing on the development of thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, decrease liver fat accumulation, and enhance liver function. THR-beta agonists are compounds that specifically activate the thyroid hormone receptor-beta subtype, a crucial receptor involved in regulating metabolism, growth, and development. For instance, in March 2024, the U.S. Food and Drug Administration (FDA) approved Rezdiffra (resmetirom), the first treatment for adults with noncirrhotic NASH and moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra aids in regulating lipid metabolism, resulting in a reduction of intrahepatic triglycerides and overall liver fat accumulation.

Prominent companies in the non-alcoholic steatohepatitis (NASH) market are actively engaged in the development of innovative products, exemplified by a focus on a thyroid hormone receptor (THR)-B selective agonist. This innovative therapeutic approach is designed to target fundamental underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor, a pivotal protein regulating gene expression upon binding with thyroid hormones, plays a crucial role in various physiological processes. A case in point is Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company, which completed the submission of a New Drug Application in July 2023, seeking accelerated approval for Resmetirom in the treatment of NASH with liver fibrosis. Resmetirom, offering once-daily oral therapy and liver-directed action, specifically targets hepatic steatosis, inflammation, and hepatocellular injury associated with NASH and liver fibrosis. Notably designated as a Breakthrough Therapy by the FDA, and supported by a comprehensive clinical development program, including Phase 3 trials, Resmetirom showcases significant potential to address unmet medical needs. This advancement positions it as a promising addition to the evolving treatment landscape for NASH with liver fibrosis.

In July 2022, Advanz Pharma Corp. Limited, a prominent UK-based pharmaceutical company, successfully acquired Intercept Pharmaceuticals Inc for an undisclosed sum. This strategic acquisition is designed to solidify Advanz Pharma's position in the rare disease treatment sector, specifically through the addition of the ex-U.S. rights to Ocaliva (obeticholic acid), an orphan medicine used for treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc., a distinguished U.S.-based biopharmaceutical company specializing in innovative therapies for progressive non-viral liver disorders, aligns well with Advanz Pharma's strategic goals in expanding its pharmaceutical portfolio.

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis (nash) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Solid; Liquid
• 2) By Product: Vitamin E and Pioglitazone; Ocaliva; Elafibranor; Selonsertib and Cenicriviroc; Other Products
• 3) By Disease Cause: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity
• 4) By Sales Channel: Hospital Pharmacy; Retail Pharmacy; Online Provider
• 5) By Application: Oral; Parenteral
• Subsegments:
• 1) By Solid: Tablets; Capsules; Other Solid Dosage Forms
• 2) By Liquid: Oral Solutions; Syrups; Injectable Solutions; Other Liquid Dosage Forms
• Companies Mentioned: NGM Biopharmaceuticals Inc.; Novartis AG; AstraZeneca plc.; GlaxoSmithKline plc.; F. Hoffmann-La Roche AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics

3. Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Alcoholic Steatohepatitis (NASH) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Alcoholic Steatohepatitis (NASH) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Alcoholic Steatohepatitis (NASH) Market Growth Rate Analysis
• 5.4. Global Non-Alcoholic Steatohepatitis (NASH) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Alcoholic Steatohepatitis (NASH) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Alcoholic Steatohepatitis (NASH) Total Addressable Market (TAM)

6. Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

• 6.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Solid
• Liquid
• 6.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vitamin E and Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib and Cenicriviroc
• Other Products
• 6.3. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity
• 6.4. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Provider
• 6.5. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.6. Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Solid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Capsules
• Other Solid Dosage Forms
• 6.7. Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Solutions
• Syrups
• Injectable Solutions
• Other Liquid Dosage Forms

7. Non-Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

• 7.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market

• 8.1. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Alcoholic Steatohepatitis (NASH) Market

• 9.1. China Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 9.2. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Alcoholic Steatohepatitis (NASH) Market

• 10.1. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis (NASH) Market

• 11.1. Japan Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 11.2. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis (NASH) Market

• 12.1. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market

• 13.1. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis (NASH) Market

• 14.1. South Korea Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 14.2. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market

• 15.1. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 15.2. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Alcoholic Steatohepatitis (NASH) Market

• 16.1. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis (NASH) Market

• 17.1. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Alcoholic Steatohepatitis (NASH) Market

• 18.1. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis (NASH) Market

• 19.1. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis (NASH) Market

• 20.1. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market

• 21.1. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 21.2. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis (NASH) Market

• 22.1. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Alcoholic Steatohepatitis (NASH) Market

• 23.1. North America Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 23.2. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Alcoholic Steatohepatitis (NASH) Market

• 24.1. USA Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 24.2. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis (NASH) Market

• 25.1. Canada Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 25.2. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Alcoholic Steatohepatitis (NASH) Market

• 26.1. South America Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 26.2. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis (NASH) Market

• 27.1. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis (NASH) Market

• 28.1. Middle East Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 28.2. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis (NASH) Market

• 29.1. Africa Non-Alcoholic Steatohepatitis (NASH) Market Overview
• 29.2. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

• 30.1. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape
• 30.2. Non-Alcoholic Steatohepatitis (NASH) Market Company Profiles
  • 30.2.1. NGM Biopharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

31. Non-Alcoholic Steatohepatitis (NASH) Market Other Major And Innovative Companies

• 31.1. The Takeda Pharmaceutical Company Limited
• 31.2. Gilead Sciences Inc.
• 31.3. Novo Nordisk A/S
• 31.4. Genfit SA
• 31.5. Cadila Pharmaceuticals Ltd.
• 31.6. Intercept Pharmaceuticals Inc.
• 31.7. Enanta Pharmaceuticals Inc.
• 31.8. Blade Therapeutics Inc.
• 31.9. Galmed Pharmaceuticals Inc.
• 31.10. Immuron Limited
• 31.11. Terns Pharmaceuticals Inc.
• 31.12. Tobira Therapeutics Inc.
• 31.13. Arena Pharmaceuticals Inc.
• 31.14. Galectin Therapeutics Inc.
• 31.15. Viking Therapeutics

32. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis (NASH) Market

35. Non-Alcoholic Steatohepatitis (NASH) Market High Potential Countries, Segments and Strategies

• 35.1 Non-Alcoholic Steatohepatitis (NASH) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Alcoholic Steatohepatitis (NASH) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Alcoholic Steatohepatitis (NASH) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer